Incannex Healthcare Limited (IXHL)
USD 0.13
(-0.15%)
USD 0.13
(-0.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 5.83 Million USD | 97.09% |
| 2023 | 2.95 Million AUD | 113.54% |
| 2022 | 1.38 Million AUD | 143.8% |
| 2021 | 567.29 Thousand AUD | -22.96% |
| 2020 | 736.35 Thousand AUD | -21.25% |
| 2019 | 935.09 Thousand AUD | -14.3% |
| 2018 | 1.09 Million AUD | -6.75% |
| 2017 | 1.17 Million AUD | 82.44% |
| 2016 | 641.35 Thousand AUD | -88.86% |
| 2015 | 5.75 Million AUD | 1.36% |
| 2014 | 5.68 Million AUD | 86.89% |
| 2013 | 3.04 Million AUD | 33.24% |
| 2012 | 2.28 Million AUD | -28.95% |
| 2011 | 3.21 Million AUD | 43.01% |
| 2010 | 2.24 Million AUD | -65.34% |
| 2009 | 6.47 Million AUD | 521.43% |
| 2008 | 1.04 Million AUD | 502.03% |
| 2007 | 173.19 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.48 Million USD | 17.88% |
| 2024 Q3 | 3.11 Million USD | -10.75% |
| 2024 Q4 | 5.83 Million USD | 67.19% |
| 2023 Q4 | 2.95 Million AUD | 0.0% |
| 2023 FY | 2.95 Million AUD | 113.54% |
| 2023 Q2 | 885.13 Thousand AUD | 0.0% |
| 2022 Q2 | 547.78 Thousand AUD | 0.0% |
| 2022 FY | 1.38 Million AUD | 143.8% |
| 2022 Q4 | 2.01 Million AUD | 0.0% |
| 2021 Q2 | 378.44 Thousand AUD | 0.0% |
| 2021 Q4 | 755.04 Thousand AUD | 0.0% |
| 2021 FY | 567.29 Thousand AUD | -22.96% |
| 2020 Q2 | 389.53 Thousand AUD | 0.0% |
| 2020 FY | 736.35 Thousand AUD | -21.25% |
| 2020 Q4 | 1.07 Million AUD | 0.0% |
| 2019 FY | 935.09 Thousand AUD | -14.3% |
| 2019 Q4 | 935.09 Thousand AUD | 0.0% |
| 2019 Q2 | 571.03 Thousand AUD | 0.0% |
| 2018 FY | 1.09 Million AUD | -6.75% |
| 2018 Q2 | 751.33 Thousand AUD | 0.0% |
| 2018 Q4 | 1.09 Million AUD | 0.0% |
| 2017 FY | 1.17 Million AUD | 82.44% |
| 2017 Q4 | 1.16 Million AUD | 0.0% |
| 2017 Q2 | 939.72 Thousand AUD | 0.0% |
| 2016 Q4 | 641.35 Thousand AUD | 300.0% |
| 2016 FY | 641.35 Thousand AUD | -88.86% |
| 2016 Q3 | 160.33 Thousand AUD | -82.64% |
| 2016 Q2 | 923.67 Thousand AUD | -35.85% |
| 2016 Q1 | 1.43 Million AUD | -75.0% |
| 2015 Q1 | 1.42 Million AUD | -75.0% |
| 2015 Q4 | 5.75 Million AUD | 300.0% |
| 2015 Q2 | 6.06 Million AUD | 326.8% |
| 2015 Q3 | 1.43 Million AUD | -76.25% |
| 2015 FY | 5.75 Million AUD | 1.36% |
| 2014 FY | 5.68 Million AUD | 86.89% |
| 2014 Q1 | 760.12 Thousand AUD | -75.0% |
| 2014 Q2 | 4.58 Million AUD | 503.17% |
| 2014 Q3 | 1.42 Million AUD | -69.01% |
| 2014 Q4 | 5.68 Million AUD | 300.0% |
| 2013 FY | 3.04 Million AUD | 33.24% |
| 2013 Q4 | 3.04 Million AUD | 300.0% |
| 2013 Q3 | 760.12 Thousand AUD | -88.74% |
| 2013 Q2 | 6.75 Million AUD | 1083.49% |
| 2013 Q1 | 570.49 Thousand AUD | -75.0% |
| 2012 Q2 | 4.38 Million AUD | 445.88% |
| 2012 FY | 2.28 Million AUD | -28.95% |
| 2012 Q4 | 2.28 Million AUD | 300.0% |
| 2012 Q3 | 570.49 Thousand AUD | -86.98% |
| 2012 Q1 | 802.92 Thousand AUD | -75.0% |
| 2011 Q1 | 561.45 Thousand AUD | -75.0% |
| 2011 Q4 | 3.21 Million AUD | 300.0% |
| 2011 FY | 3.21 Million AUD | 43.01% |
| 2011 Q3 | 802.92 Thousand AUD | -78.85% |
| 2011 Q2 | 3.79 Million AUD | 576.21% |
| 2010 Q4 | 2.24 Million AUD | 300.0% |
| 2010 Q2 | 8.06 Million AUD | 398.14% |
| 2010 Q1 | 1.61 Million AUD | -75.0% |
| 2010 FY | 2.24 Million AUD | -65.34% |
| 2010 Q3 | 561.45 Thousand AUD | -93.04% |
| 2009 Q4 | 6.47 Million AUD | 300.0% |
| 2009 Q3 | 1.61 Million AUD | 125.3% |
| 2009 Q2 | 718.99 Thousand AUD | 175.83% |
| 2009 FY | 6.47 Million AUD | 521.43% |
| 2009 Q1 | 260.66 Thousand AUD | -75.0% |
| 2008 Q2 | 247.01 Thousand AUD | 470.52% |
| 2008 Q4 | 1.04 Million AUD | 300.0% |
| 2008 FY | 1.04 Million AUD | 502.03% |
| 2008 Q1 | 43.29 Thousand AUD | -75.0% |
| 2008 Q3 | 260.66 Thousand AUD | 5.52% |
| 2007 FY | 173.19 Thousand AUD | 0.0% |
| 2007 Q4 | 173.19 Thousand AUD | 300.01% |
| 2007 Q3 | 43.29 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 98.764% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 96.443% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.385% |
| Cosmos Health Inc. | 30.25 Million USD | 80.729% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 31.335% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 99.118% |
| Cronos Group Inc. | 43.73 Million USD | 86.67% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 87.966% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 97.348% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -2555.891% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | 5.043% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | 5.043% |
| SCYNEXIS, Inc. | 55.45 Million USD | 89.486% |
| Safety Shot Inc | 3.89 Million USD | -49.793% |
| Theratechnologies Inc. | 98.63 Million USD | 94.09% |
| Alpha Teknova, Inc. | 38.55 Million USD | 84.877% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 57.613% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 99.172% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 33.417% |
| Dynavax Technologies Corporation | 375.02 Million USD | 98.445% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 99.287% |
| Radius Health, Inc. | 804.29 Million USD | 99.275% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 36.607% |
| Alvotech | 1.88 Billion USD | 99.69% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 95.741% |
| SIGA Technologies, Inc. | 57.97 Million USD | 89.944% |
| Shineco, Inc. | 47.6 Million USD | 87.753% |
| Silver Spike Investment Corp. | 3 Million USD | -93.699% |
| Journey Medical Corporation | 56.49 Million USD | 89.681% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 72.649% |
| Embecta Corp. | 2.03 Billion USD | 99.714% |
| Harrow Health, Inc. | 241.75 Million USD | 97.588% |
| Procaps Group, S.A. | 462.06 Million USD | 98.738% |
| Biofrontera Inc. | 23.13 Million USD | 74.804% |
| DURECT Corporation | 30.4 Million USD | 80.826% |
| PainReform Ltd. | 2.69 Million USD | -116.648% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.804% |
| OptiNose, Inc. | 194.33 Million USD | 97.0% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 72.209% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 96.785% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 88.899% |
| ProPhase Labs, Inc. | 42.54 Million USD | 86.297% |
| Phibro Animal Health Corporation | 725.54 Million USD | 99.196% |
| Procaps Group S.A. | 462.06 Million USD | 98.738% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 58.422% |
| Viatris Inc. | 27.21 Billion USD | 99.979% |
| Rockwell Medical, Inc. | 30.88 Million USD | 81.122% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 93.549% |
| Tilray Brands, Inc. | 892.11 Million USD | 99.346% |
| PetIQ, Inc. | 645.22 Million USD | 99.096% |
| Talphera, Inc. | 6.29 Million USD | 7.313% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.428% |
| Alimera Sciences, Inc. | 107.35 Million USD | 94.569% |
| Assertio Holdings, Inc. | 148.41 Million USD | 96.072% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -207.495% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 96.638% |
| Hempacco Co., Inc. | 18.82 Million USD | 69.026% |
| Alvotech | 1.88 Billion USD | 99.69% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 99.302% |
| Kamada Ltd. | 109.96 Million USD | 94.698% |
| Currenc Group, Inc. | 177.67 Million USD | 96.719% |
| Indivior PLC | 1.95 Billion USD | 99.701% |
| Evoke Pharma, Inc. | 9.64 Million USD | 39.573% |
| Flora Growth Corp. | 17.22 Million USD | 66.148% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 31.335% |
| Evolus, Inc. | 209.68 Million USD | 97.22% |
| HUTCHMED (China) Limited | 536.38 Million USD | 98.913% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.333% |
| Akanda Corp. | 12.66 Million USD | 53.982% |